AGEN Agenus Inc
Price (delayed)
$1.61
Market cap
$40.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.59
Enterprise value
$90.48M
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the
Highlights
The EPS is up by 23% year-on-year and by 3.4% since the previous quarter
AGEN's net income is up by 8% YoY
The quick ratio has plunged by 55% YoY but it has increased by 6% from the previous quarter
AGEN's equity has shrunk by 104% YoY and by 12% QoQ
Agenus's revenue has decreased by 36% from the previous quarter and by 34% YoY
Key stats
What are the main financial stats of AGEN
Market
Valuations
Earnings
Shares outstanding
25.31M
Market cap
$40.75M
Enterprise value
$90.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.87
Revenue
$103.46M
Gross profit
$102.98M
Operating income
-$124.43M
Net income
-$227.21M
EBIT
-$109.59M
EBITDA
-$96.24M
Free cash flow
-$158.87M
Per share
Balance sheet
Liquidity
EPS
-$10.59
EPS diluted
-$10.59
Free cash flow per share
-$7.4
Book value per share
-$13.91
Revenue per share
$4.82
TBVPS
$9.26
Total assets
$226.27M
Total liabilities
$532.7M
Debt
$90.17M
Equity
-$326.38M
Working capital
-$175.83M
Debt to equity
-0.28
Current ratio
0.21
Quick ratio
0.18
Net debt/EBITDA
-0.52
Margins
Efficiency
Dividend
EBITDA margin
-93%
Gross margin
99.5%
Net margin
-219.6%
Operating margin
-120.3%
Return on assets
-89.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-2,250.2%
Return on sales
-105.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGEN stock price
How has the Agenus stock price performed over time
Intraday
6.98%
1 week
-3.59%
1 month
-43.51%
1 year
-86.3%
YTD
-41.24%
QTD
6.98%
Financial performance
How have Agenus's revenue and profit performed over time
Revenue
$103.46M
Gross profit
$102.98M
Operating income
-$124.43M
Net income
-$227.21M
Gross margin
99.5%
Net margin
-219.6%
AGEN's operating margin has plunged by 92% from the previous quarter and by 17% YoY
Agenus's net margin has shrunk by 55% QoQ and by 40% YoY
Agenus's revenue has decreased by 36% from the previous quarter and by 34% YoY
The gross profit has contracted by 36% from the previous quarter and by 33% YoY
Growth
What is Agenus's growth rate over time
Valuation
What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
0.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.87
The EPS is up by 23% year-on-year and by 3.4% since the previous quarter
AGEN's equity has shrunk by 104% YoY and by 12% QoQ
The stock's price to sales (P/S) is 94% less than its 5-year quarterly average of 4.8 and 74% less than its last 4 quarters average of 1.2
Agenus's revenue has decreased by 36% from the previous quarter and by 34% YoY
Efficiency
How efficient is Agenus business performance
The return on sales has dropped by 96% since the previous quarter and by 12% year-on-year
Agenus's return on assets has decreased by 32% YoY and by 8% QoQ
Dividends
What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGEN.
Financial health
How did Agenus financials performed over time
AGEN's total assets is 58% lower than its total liabilities
The quick ratio has plunged by 55% YoY but it has increased by 6% from the previous quarter
Agenus's current ratio has shrunk by 52% YoY but it has increased by 11% QoQ
Agenus's debt is 128% higher than its equity
AGEN's equity has shrunk by 104% YoY and by 12% QoQ
The debt to equity is up by 43% year-on-year but it has declined by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.